Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.

Bosch A, Bertran SP, Lu Y, Garcia A, Jones AM, Dawson MI, Farias EF.

Breast Cancer Res. 2012 Aug 24;14(4):R121. doi: 10.1186/bcr3247.

2.

TGF beta regulation of cell proliferation.

Moses HL, Arteaga CL, Alexandrow MG, Dagnino L, Kawabata M, Pierce DF Jr, Serra R.

Princess Takamatsu Symp. 1994;24:250-63. Review.

PMID:
8983080
3.

MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer.

Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, Taneja NK, Inoue K.

Expert Rev Mol Diagn. 2009 Jul;9(5):423-40. doi: 10.1586/erm.09.31. Review.

4.

Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases.

Zhou TB, Drummen GP, Jiang ZP, Long YB, Qin YH.

J Recept Signal Transduct Res. 2013 Dec;33(6):349-52. doi: 10.3109/10799893.2013.838786. Epub 2013 Sep 19. Review.

PMID:
24050824
5.

β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer.

Lahlou H, Muller WJ.

Breast Cancer Res. 2011;13(6):229. doi: 10.1186/bcr2905. Epub 2011 Nov 30. Review.

6.

Regulation of CD8(+) T cell functions by RARgamma.

Gordy C, Dzhagalov I, He YW.

Semin Immunol. 2009 Feb;21(1):2-7. doi: 10.1016/j.smim.2008.07.002. Epub 2008 Aug 20. Review.

7.

MYC in breast tumor progression.

Chen Y, Olopade OI.

Expert Rev Anticancer Ther. 2008 Oct;8(10):1689-98. doi: 10.1586/14737140.8.10.1689. Review.

8.

The role of myc oncogenes in cell growth and differentiation.

Littlewood TD, Evan GI.

Adv Dent Res. 1990 Jun;4:69-79. Review. Erratum in: Adv Dent Res 1991 Dec;5:87.

PMID:
2206213
9.

MYC activation is a hallmark of cancer initiation and maintenance.

Gabay M, Li Y, Felsher DW.

Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a014241. doi: 10.1101/cshperspect.a014241. Review.

10.

The molecular physiology of nuclear retinoic acid receptors. From health to disease.

Duong V, Rochette-Egly C.

Biochim Biophys Acta. 2011 Aug;1812(8):1023-31. doi: 10.1016/j.bbadis.2010.10.007. Epub 2010 Oct 20. Review.

11.

Small non-coding RNAs govern mammary gland tumorigenesis.

Yu Z, Pestell RG.

J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):59-64. doi: 10.1007/s10911-012-9246-4. Epub 2012 Mar 1. Review.

12.

Genetically engineered mice as experimental tools to dissect the critical events in breast cancer.

Menezes ME, Das SK, Emdad L, Windle JJ, Wang XY, Sarkar D, Fisher PB.

Adv Cancer Res. 2014;121:331-82. doi: 10.1016/B978-0-12-800249-0.00008-1. Review.

13.

Oncogenes in cell survival and cell death.

Shortt J, Johnstone RW.

Cold Spring Harb Perspect Biol. 2012 Dec 1;4(12). pii: a009829. doi: 10.1101/cshperspect.a009829. Review.

14.

Inactivation of MYC reverses tumorigenesis.

Li Y, Casey SC, Felsher DW.

J Intern Med. 2014 Jul;276(1):52-60. doi: 10.1111/joim.12237. Review.

15.

The Quest for Targets Executing MYC-Dependent Cell Transformation.

Hartl M.

Front Oncol. 2016 Jun 2;6:132. doi: 10.3389/fonc.2016.00132. eCollection 2016. Review.

16.

Recent advances in cancer research: mouse models of tumorigenesis.

Herzig M, Christofori G.

Biochim Biophys Acta. 2002 Jun 21;1602(2):97-113. Review.

PMID:
12020798
17.

Validation: the new challenge for pathology.

Cardiff RD, Rosner A, Hogarth MA, Galvez JJ, Borowsky AD, Gregg JP.

Toxicol Pathol. 2004 Mar-Apr;32 Suppl 1:31-9. Review.

PMID:
15209401
18.

MYC in Regulating Immunity: Metabolism and Beyond.

Gnanaprakasam JN, Wang R.

Genes (Basel). 2017 Feb 25;8(3). pii: E88. doi: 10.3390/genes8030088. Review.

19.

Roles of N-Myc and STAT interactor in cancer: From initiation to dissemination.

Pruitt HC, Devine DJ, Samant RS.

Int J Cancer. 2016 Aug 1;139(3):491-500. doi: 10.1002/ijc.30043. Epub 2016 Mar 11. Review.

Supplemental Content

Support Center